Did you miss the July 5th issues of the Ophthalmology Times eReport? In this e-newsletter we released information on Bevacizumab (Avastin, Genentech) monotherapy for zone I retinopathy of prematurity, gender difference in presbyopia assistance, a scholarship for the “most beautiful eyes” and more. Check out the articles in this issue below.
Bevacizumab (Avastin, Genentech) monotherapy for zone I retinopathy of prematurity (ROP) might have potential for treating pre-term infants who are in phase II of the pathogenesis of ROP. Read more
Ophthalmologists should consider gender differences in arm length and reading distance preferences when prescribing reading glasses or bifocal lenses, according to a recent study published in Investigative Ophthalmology & Visual Science. Such factors mean that women tend to desire assistance with presbyopia symptoms earlier than men do. Read more
George B. Bartley, MD, will succeed Andrew P. Schachat, MD, as editor-in-chief of Ophthalmology, the American Academy of Ophthalmology’s (AAO’s) flagship journal, in January. Dr. Schachat has served in this capacity since 2003. Read more
A $10,000 educational scholarship is up for grabs in Prevent Blindness America’s (PBA’s) 2012 Most Beautiful Eyes Contest. Read more
Synergetics USA Inc. has received 510(k) marketing clearance from the FDA for its proprietary vitrectomy system (VersaVIT). Read more
Acucela Inc. has been named as a recipient of the 2012 Emerging Leaders award from the Japan-U.S. Innovation Awards. Read more
NicOx S.A. and Rapid Pathogen Screening Inc (RPS) have entered into a licensing agreement that gives NicOx access to RPS’s point-of-care ocular diagnostic tests. Read more